Literature DB >> 20001344

Is female adnexal tumour of probable wolffian origin a benign lesion? A systematic review of the English literature.

Mark K Heatley1.   

Abstract

AIMS: To establish the prognosis associated with female adnexal tumour of probable wolffian origin (FATWO) and determine the frequency with which it behaves as a truly benign lesion.
METHODS: Medline and Embase electronic databases were interrogated to identify 31 papers describing 63 patients with FATWO with follow up.
RESULTS: Fifty (79%, CI 67.4-87.3%) were alive and well but seven patients had recurrent or residual disease (11.1%, CI 5.6-21.5%) and three had died of disease (4.8%, CI 1.6-13.1%). Stage (p = 0.0002) and differentiation (p = 0.0118) showed a significant association with outcome although atypia approached significance at the 5% level (p = 0.0658). One patient with a ruptured tumour had recurrent disease and one other had died of disease (p = 0.2278). There was no association between outcome and age (p = 0.6651), size (p = 0.1912), length of survival (p = 0.2351) tumour site, mitotic rate or necrosis (p = 0.5937, 0.4697 and 0.2016, respectively).
CONCLUSION: On the basis of these findings, FATWO cannot be regarded as a benign lesion. These lesions may be confused with well differentiated gynaecological cancers and careful clinicopathological correlation with the extensive use of immunohistochemistry is encouraged to ensure that lesions such as extragonadal endometrioid adenocarcinoma is not confused with FATWO.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20001344     DOI: 10.3109/00313020903273084

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  9 in total

1.  [Tumor of the mesosalpinx with unclear differentiation].

Authors:  D Nann; S Gahlen; H G Keul; H J Voigt; F Fend; A Staebler
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

2.  Female adnexal tumor of probable Wolffian origin (FATWO) with recurrence 3 years postsurgery.

Authors:  Susanna Syriac; Nicole Durie; Joshua Kesterson; Shashrikant Lele; Paulette Mhawech-Fauceglia
Journal:  Int J Gynecol Pathol       Date:  2011-05       Impact factor: 2.762

3.  RARE MALIGNANT FEMALE ADNEXAL TUMOR OF WOLFFIAN ORIGIN (FATWO) WITH MULTIPLE RELAPSES AND CHEMOTHERAPY REGIMENS.

Authors:  A Piciu; C Cainap; D Sur; A Havasi; B Fetica; O Balacescu; A Mester; S Cainap
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Apr-Jun       Impact factor: 0.877

4.  Rare giant female adnexal tumor of probable Wolffian origin: a case report.

Authors:  Sanela Brzika; Ismar Rašić; Admir Bektešević; Ali Gavrankapetanović; Nedim Hasić; Salko Pašović
Journal:  J Surg Case Rep       Date:  2022-05-27

5.  A female adnexal tumor of probable Wolffian origin showing positive O-6-methylguanine-DNA methyltransferase methylation.

Authors:  Min Jung Kwon; Min Jeong Yun; Min Kyu Kim
Journal:  Obstet Gynecol Sci       Date:  2016-07-13

6.  Diagnosis and management of female adnexal tumor of probable Wolffian origin (FATWO) arising from ovary: a case report.

Authors:  Ayse Figen Türkçapar; Berna Seçkin; Tayfun Güngör; Levent Sirvan; Leyla Mollamahmutoğlu
Journal:  J Turk Ger Gynecol Assoc       Date:  2013-03-01

7.  Female adnexal tumour of probable Wolffian origin: a rare entity with challenging histopathological diagnosis and unpredictable behaviour.

Authors:  Alina Seixas; David Tente; Evelin Pinto; João Gonçalves
Journal:  BMJ Case Rep       Date:  2020-10-04

8.  Recurrent female adnexal tumor of probable Wolffian origin treated with debulking surgery, imatinib and paclitaxel/carboplatin combination chemotherapy: A case report.

Authors:  Akihiko Wakayama; Hirofumi Matsumoto; Hajime Aoyama; Masanao Saio; Ayumi Kumagai; Takuma Ooyama; Morihiko Inamine; Yoichi Aoki
Journal:  Oncol Lett       Date:  2017-03-17       Impact factor: 2.967

9.  Large Wolffian adnexal tumor of the ovary: A case report and literature review.

Authors:  Ya-Qiong Du; Shu-Zheng Song; Xiao-Chun Ni; Ju-Gang Wu; Shou-Lian Wang; Bo-Jian Jiang; Ji-Wei Yu
Journal:  Oncol Lett       Date:  2017-08-31       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.